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tributed equally tAbstract Thienorphine (TNP) is a new partial opioid agonist currently developed as a promising drug
candidate with the intended clinical indication for the treatment of opioid dependence. The pharmaco-
kinetic proﬁle and biliary excretion of TNP and its glucuronide conjugate (TNP-Glu) were investigated
after oral administration of TNP in rats. The concentrations of TNP and TNP-Glu were simultaneously
quantiﬁed using a LC-MS/MS method. A double peak phenomenon was observed in TNP plasma
concentration–time curves with the secondary peak appeared at 6–8 h. A slower decline of plasma
concentrations in the terminal phase was observed for TNP with T1/2 of 7.01 h. TNP-Glu was the
predominant component in rat plasma and bile. Its plasma level was about 10 times higher than TNP and
the 24 h accumulative bile excretion rate was 23%. Enterohepatic circulation of TNP and TNP-Glu was
evaluated using a paired rat model. In bile-donor rats, no double-peak was detected and the elimination
half life of TNP was signiﬁcantly shortened (3.71 h) when compared to intact rats (7.01 h, Po0.05). Both
TNP and TNP-Glu were detected in bile-recipient rats. Their exposures in recipient rats due to entero-
hepatic circulation were 15.6% and 42.6% for the parent drug and the metabolite, respectively. The
deconjugation of the glucuronide conjugate and the reabsorption of free TNP were further conﬁrmed in
in situ perfused rat intestinal preparations. These results indicate that the enterohepatic circulation has a
signiﬁcant inﬂuence on the systemic exposure of the parent drug and its glucuronide conjugate,
particularly on the terminal elimination of TNP, which may result in the prolonged retention of the drug
in body.
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Thienorphine, [N-cyclopropylmethyl-7(-[(R)-1-hydroxy-1-methyl-
3-(thien-2-yl)-propyl]-6, 14-endo-ethanotetrahydronororipavine]
(TNP, Fig. 1A), is a buprenorphine analog discovered by Chinese
scientists1. It has been proved to be a non-selective partial opioid
agonist. In a comparative pharmacological study, TNP showed
several advantages over buprenorphine2, including higher binding
afﬁnity at m-opioid receptor in vitro, higher antinociceptive
efﬁcacy and better oral bioavailability in vivo. It also demon-
strated a much longer antagonism (14 days) on morphine-induced
lethality when compared to buprenorphine. Co-administration of
TNP with morphine dose-dependently suppressed the develop-
ment, transfer and expression of behavioral sensitization to
morphine in mice3. In a binding study, TNP displayed high
afﬁnity for k-, m-, and d-opioid receptors with Ki values of 0.14,
0.22 and 0.69 nM, respectively. It also partially stimulated m-
opioid and k-opioid receptors but not d-opioid receptors4. In the
animal models of conditioned place preference and self-adminis-
tration, neither dependent liability nor suppressed morphine-
induced behaviors was observed for TNP5. TNP is currently
under clinical evaluation as a promising drug candidate for
treatment of opioid dependence.
The absorption, distribution, metabolism and excretion of
TNP have been studied extensively in pre-clinical animals.
Although the oral bioavailability of TNP was improved over
buprenorphine, its plasma concentration was only at lower
ng/mL level for most time points on concentration–time
curves after an oral dose of 3 mg/kg, and the bioavailability
was marginal (9.7%)6. This was partially due to its extensive
metabolism in gut and liver, and a number of oxidative and
conjugated metabolites were detected in vitro and in vivo7,8.
The glucuronide conjugate (TNP-Glu) was the major meta-
bolite in the circulation with the peak level about one order of
magnitude higher than the parent drug in rats. A double-peak
phenomenon for TNP in concentration–time curves was
observed in both experimental animals and human with the
secondary peak appeared usually at 6–8 h post-dose. The
terminal elimination of TNP was slow in relation to its plasma
concentration with T1/247 h. In an excretion study with
3H
labeled compound, a signiﬁcant amount of radioactivity (26%
in 24 h) was recovered from the bile after oral administration
of 3H-TNP to bile-duct cannulated (BDC) rats. The excretion
of the radioactivity from feces was lasted for about two weeks
(data not published). The results above indicate that bile
excretion was an important elimination pathway for TNP.Figure 1 Chemical structures of TNPDouble-peak and slower terminal elimination of TNP might
be associated with the process of enterohepatic circulation,
which may consequently inﬂuence the TNP disposition and
contribute to the prolonged retention of the drug in body.
Enterohepatic circulation (EHC) occurs by biliary excretion
and intestinal reabsorption of a drug, sometimes with hepatic
or intestinal conjugation and intestinal deconjugation9. It
affects the pharmacokinetics of drugs by inﬂuencing terminal
half-life, the area under the plasma concentration–time curve
and bioavailability10,11. In the present study, the biliary
excretion of TNP and its glucuronide was investigated using
the non-labeled TNP in BDC rats. The decomposition of the
glucuronide and the reabsorption of TNP were studied in
in situ vascularly perfused rat intestinal preparations. The
effect of EHC on the overall disposition of TNP in rat was
assessed using paired rat model, in which TNP was orally
administrated to bile-donor rats with their bile ﬂowed directly
into the duodenum of bile-recipient rats via surgically implanted
catheters.2. Materials and methods
2.1. Chemicals
Thienorphine hydrochloride (TNP, 99.5% in purity, Fig. 1A)
and thienorphine-3-glucuronide (TNP-Glu, 99% in purity,
Fig. 1B) was supplied by the chemical synthesis laboratory
of the Institute. Buprenorphine hydrochloride (internal stan-
dard, IS) and bovine serum albumin were purchased from
Sigma (St. Louis, MO, USA). Dextran-40 and glucose were
the products from the Fourth Pharmaceutical Company
(Shijiazhuang, China) and Jingxi Chemicals Ltd. (Beijing,
China), respectively. Acetonitrile was of HPLC grade (J&K
Chemical LTD) and other reagents were all of analytical
grade.
2.2. Animals
Adults, male Sprague-Dawley rats weighing 320720 g were
obtained from the Beijing Experimental Animal Center. The
animal experiments were carried out in the Beijing Center for
Drug Safety Evaluation, in accordance with a protocol
approved by the Institutional Animal Care and Use Commit-
tee of the Center, which is in compliance with the guidelines
of the Association for Assessment and Accreditation of(A) and TNP-3-glucuronide (B).
Jingting Deng et al.176Laboratory Animal Care International (AAALAC). The rats
were fasted 12 h prior to experiments. Fresh water was
supplied ad libitum.
2.3. Animal experiments
BDC rats were surgically prepared under anesthesia. A
catheter (PE-10) was inserted directly into the proximal
portion of the bile duct toward the liver. The free end of
catheter was secured in place by ligation with surgical sutures
and exteriorized subcutaneously at the back of the rats for
collection of bile samples. The BDC rats were allowed to
recovery for 3 day before dosing. The bile samples were
collected from the catheter at pre-scheduled time intervals.
The surgical procedure of the paired-rat model for EHC
studies was performed according to the methods reported by
Chen et al.12. A donor rat (for drug dosing) and a recipient rat
(for receiving bile) remained anesthetized throughout the
experiment period with body temperatures maintained at
37 1C. The bile duct of the donor rat was cannulated proximal
to the liver with a catheter (PE—0.85 mm/0.42 mm). The other
catheter (PE—1.2 mm/0.8 mm) was inserted directly into the
duodenum of the recipient rat. The rats were paired by
connecting the two catheters before dosing.
The in situ perfused rat intestinal model was prepared as per
the procedure introduced by Pang et al.13 with slight mod-
iﬁcation for ﬁtting to local operational conditions. Brieﬂy, a
cannula (PE—0.85 mm/0.42 mm) was inserted into the right
renal artery, through the aorta, and then into the superior
mesenteric artery for inﬂow. The portal vein was catheterized
with the tip of another catheter (PE—1.2 mm/0.8 mm) facing
the venous return from the intestine for outﬂow. The aorta
and inferior vena cava were then ligated. The temperature of
the in situ preparation was maintained at 37 1C. Perfusate
consisted of 4% bovine serum albumin, 0.1% dextran-40 and
0.3% glucose in Krebs-Ringer bicarbonate buffer solution (pH
7.4) and oxygenated with carbogen (95%O2/5%CO2). Every
100 mL perfusate was added with 40 mL dexamethasone and
20 mL noradrenaline injection solutions before perfusion.
2.4. Administration and sample collection
Rats were divided into 5 groups. (1) Oral pharmacokinetic study
group: intact rats received a single oral dose of TNP (3 mg/kg
suspended in 5% CMC) and blood samples (200 mL each) were
collected from the jugular vein at 0.25, 0.5, 1, 2, 4, 6, 8, 12 and
24 h post-dose (n¼5). (2) BDC rat control group for bile
collection: blank bile samples were collected from the BDC rats
for the period of 24 h (n¼5). (3) BDC rats group for biliary
excretion study: the bile samples were collected at time intervals
of 0–1, 1–2, 2–4, 4–6, 6–8, 8–12 and 12–24 h after the BDC rats
(n¼5) were orally dosed with TNP (3 mg/kg). An aliquot of
50 mL bile was taken from each sample and quantitatively
analyzed by LC-MS/MS for TNP and its glucuronide. The
remained bile samples were combined to obtained composite bile
samples, and the contents in the bile were quantitatively mea-
sured. (4) Paired-rat group for in vivo EHC study: approximately
10 min before dosing the cannulated rats were paired by
connecting the bile cannula of the donor rats to the duodenal
cannula of the recipient rats (n¼4). After an intraduodenal dose
of 3 mg/kg TNP to the donor rats, plasma samples were takenseparately from bile-donor and bile-recipient rats at 0.25, 0.5, 1, 2,
4, 8, 12, 16 and 24 h, and bile samples were taken from bile-
recipient rats at time intervals of 0–1, 1–2, 2–4, 4–6, 6–8, 8–12 and
12–24 h post-dose. An aliquot of 50 mL bile was taken from each
sample for analysis. (5) The in situ rat intestinal perfusion group:
the in situ vascularly perfusions of the rat intestinal preparations
were performed after intraduodenally dosing with the blank bile
spiked with 1 mg TNP-Glu and the composite bile (equivalent to
1 mg TNP-Glu) from the Group 3 (n¼3 each). Perfusate samples
(100 mL each) were collected from the reservoir at 0.25, 0.5, 1, 1.5,
2, 2.5 and 3 h and analyzed to assess the intestinal deconjugation
of the glucuronide and reabsorption of TNP.
2.5. LC-MS/MS analysis of TNP and its glucuronide
The LC-MS/MS system used was a Thermo Finnigan TSQ
Quantum Discovery MAX triple-quadrupole tandem mass
spectrometer coupled with a Finnigan surveyor LC pump and
a Surveyor AS autosampler (Thermo Finnigan, USA). Data
acquisition and processing were carried out using Xcalibur 1.4
and LCQuan 2.0 software supplied by Thermo-Finnigan. The
quantitative analysis of TNP and its metabolite were per-
formed as per the previously reported method6,8. An aliquot
of samples (100 mL for plasma and perfusate, 50 mL for bile)
was mixed with 3-fold volume of methanol–acetonitrile (1:4, v/v)
containing 100 mg/L internal standard to precipitate proteins. The
sample was centrifuged at 4 1C, 20,200 g for 10 min, and then
10 mL of supernatant was injected onto LC-MS/MS for analysis.
The chromatographic separation was carried out on a Bata Basic-
C18 column (150 mm 2.1 mm ID, 5 mm, Finnigan, USA) with
the mobile phase consisting of equal volumes of 0.1% formic acid
in 5 mM ammonium formate solution and 0.1% formic acid in
acetonitrile. The ﬂow rate was set at 0.2 mL/min. The Mass
spectrometer was operated in positive mode (ESIþ). Quantiﬁca-
tion was performed using selected reaction monitoring (SRM)
with the transitions of m/z 522-m/z 97 and 504 for TNP, m/z
698-m/z 522 for its glucuronide conjugate, m/z 468-m/z 396
and 414 for IS. Under above optimized analysis conditions, no
signiﬁcant endogenous interferences were detected at the peak
regions for TNP, TNP-Glu and IS in all the biological specimens.
Calibration curves were linear over the concentration ranges of
0.5–50 ng/mL for TNP and 2–500 ng/mL for TNP-Glu, with the
correlation coefﬁcient values (r2) greater than 0.99. The lower
limits of quantiﬁcation were 0.5 and 2 ng/mL for the parent drug
and the metabolite, respectively. The intra and inter-day preci-
sions (RSD) were all within 12% and the assay accuracies were in
the range from 85% to 110%. The recovery of the analytes was
above 80%.
2.6. Data analysis
The pharmacokinetic parameters of TNP and its metabolite
were determined by ﬁtting concentration–time data to non-
compartmental analysis in WinNonlins (version 5.2.1, Phar-
sight Corp, CA, USA,). The percentage of the exposure to
TNP and TNP-Glu due to enterohepatic recirculation (%EC)
was determined using the ratio of AUC0–t of bile-recipient rats
relative to the sum of AUC0–t calculated for both bile-donor
and bile-recipient rats10. Statistical analyses were performed
using unpaired Student’s t-tests. Unless otherwise indicated,
all data were expressed as mean7standard deviation (SD).
Table 1 Oral pharmacokinetic parameters of TNP and
TNP-Glu in intact rats.
Parameter TNP TNP-Glu
AUC0-t (ng  h/mL) 48.276.54 273.5795.7
Cmax (ng/mL) 7.2871.65 68.91727.13
Tmax (h) 2.0 1.0
T1/2 (h) 7.0171.84 4.8671.43
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3.1. Pharmacokinetics and biliary excretion of TNP
and TNP-Glu
The mean plasma concentration–time curves of TNP and its
conjugated metabolite in intact rats were shown in Fig. 2.
Pharmacokinetic parameters were provided in Table 1. After a
single oral dose (3 mg/kg), the ﬁrst peak concentration of TNP
(Cmax, 7.2871.65 ng/mL) in plasma was reached at 2 h. After
the initial absorption phase, the mean plasma concentration of
TNP displayed a second small peak at 8 h, followed by a
slower decline. The terminal elimination of TNP was pro-
longed with the T1/2 of 7.0171.84 h. The plasma concentra-
tion of TNP-Glu was about 10 times higher than the parent
drug. The Cmax (68.91727.13 ng/mL) of TNP-Glu appeared
at about 1 h and its T1/2 was 4.8671.43 h. The exposure of
TNP-Glu (AUC) was 5.7 times of that for TNP.
The biliary excretion of TNP was assessed in BDC rats with
non-labeled TNP. The quantiﬁcation of TNP and its metabo-
lites were conducted using a validated LC-MS/MS method.
Cumulative excretion proﬁles of TNP and its glucuronide are
presented in Fig. 3. TNP-Glu was the predominant compo-
nent in the bile and its recovery within 24 h was up to 23% of
the TNP dose applied. The highest bile efﬂux velocity of TNP-
Glu occurred in the ﬁrst hour. While the bile excretion of TNP
was minor, amounting to only less than 0.1% of the dose. A
number of oxidative metabolites were detected in the bile,
including N-dealkylated metabolite, mono-oxidated and di-
oxidated metabolite. Their total excretion rate was estimated
to be less than 3%, based on the rate difference between the
radioactivity study and the present study.Figure 3 Cumulative biliary excretion of TNP and its glucur-
onide conjugate in 24 h after bile-duct cannulated rats received an
oral dose of 3 mg/kg TNP.3.2. Enterohepatic recirculation of TNP and TNP-Glu
in paired rat model
The high hepatobiliary excretion rate of TNP-Glu suggests
that it may undergo enterohepatic circulation. In the paired
rat study with oral administration of TNP to bile-donor rats,
pharmacokinetic proﬁles of TNP and TNP-Glu in bile-donor
and bile-recipient rats were determined (Fig. 4). Pharmacoki-
netic parameters are presented in Table 2. TNP-Glu reached
the peak level (70.477.3 ng/mL) at 2 h in bile-donor rats,
followed by a quick decline. The plasma concentration of TNPFigure 2 Mean plasma concentration–time curves of TNP (A) and TN
n¼5).was much lower than TNP-Glu and no second peak was
observed in the time interval of 6–8 h. The elimination half life
(T1/2) of the bile-donor rat was 3.71 h, which was signiﬁcantly
shorter than the intact rats (Po0.05). Bile-recipient rats
showed a signiﬁcant plasma peak of TNP-Glu (25.8 ng/mL)
at 8 h, corresponding to the time of second TNP plasma peak
for the intact rats. The elimination of TNP-Glu in the bile-
recipient rats was slower than that in the bile-donor rats and
T1/2 was411 h. TNP was detectable in the plasma of bile-
recipient rats. The concentration was kept at a low level (ng/mL)
for the whole period of the study and did not display a signiﬁcant
peak. The exposures of TNP and TNP-Glu in bile-recipient rats
due to enterohepatic circulation (%EC) were 15.6% andP-Glu (B) in rats after an oral dose (3 mg/kg) of TNP (mean7SD,
Figure 4 Mean plasma concentration–time proﬁles of TNP and TNP-Glu in bile-donor rats (A) and bile-recipient rats (B) after oral
administration of TNP (3 mg/kg) to bile-donor rats (n¼4).
Table 2 Pharmacokinetic parameters of TNP and TNP-Glu in paired rats after bile-donor rats received an oral dose (3 mg/kg) of
TNP (n¼4).
Parameter Bile-donor rat Bile-recipient rat
TNP TNP-Glu TNP TNP-Glu
AUC0t (ng/mL) 110.3712.7 435.2791.3 20.474.3 323.8743.4
Cmax (ng  h/mL) 21.572.26 70.477.3 1.570.1 25.873.4
Tmax (h) 2 2 8 8
T1/2 (h) 3.7171.42 4.8471.89 –
a 11.6371.76
EC (%) –a –a 15.6 42.6
aNot applicable.
Jingting Deng et al.17842.6% respectively, which were determined based on the AUC0t
values of bile-donor and bile-recipient rats.
The bile samples were collected and analyzed for the bile-
recipient rats. The highest elimination rate of TNP-Glu in the
bile was noted in the 12–16 h interval. The 24 h accumulated
excretion rates for TNP-Glu and TNP were 9.04% and 3.94% of
the dose received by the bile-donor rat. The bile excretion rate of
TNP-Glu in the bile-recipient rats was about 40% of the rate for
the intact rats, comparable with the %EC value calculated.3.3. Deconjugation of TNP-Glu in in situ perfused rat
intestinal preparation
In the paired rat study, TNP-Glu had a higher exposure in the
plasma of bile-recipient rats, while a much lower plasma
concentration was seen for the parent drug, which might be
caused by slower enzymatic hydrolysis of TNP-Glu in the
intestine or quick metabolism of TNP by the liver. In order to
conﬁrm the deconjugation of TNP-Glu in the intestine and
evaluate the degree of TNP reabsorption, a further investiga-
tion was conducted using in situ perfused rat intestinal
preparations.
Mean perfusate concentration–time proﬁles of TNP are
shown in Fig. 5. TNP could be detected at 15 min of
perfusion. Its concentration was gradually increased to reach
the highest level at the end of perfusion (3 h). The free TNP
concentration was as high as 28.976 ng/mL for the intestinal
preparations that dosed with the spike bile, and the totalexposure of TNP in the perfusate was counted as 12% of the
TNP-Glu dose based on the AUC of the concentration–time
curves. In the case of duodenal injection with the composite
bile obtained from the BDC rats, the highest perfusate
concentration of TNP was 1874.8 ng/mL. Similar to the
in vivo studies, TNP-Glu was the principal substance in the
perfusates and it was absorbed rapidly from the intestinal
preparation. The highest concentrations measured at 3 h were
10177179 ng/mL for the spiked bile and 6607157 ng/mL for
the composite bile.
A number of oxidative metabolites, including dealkylated
TNP, mono and di-oxidative metabolites were also detected in
the perfusates of the intestinal preparation dosed with the
spiked bile. The results above indicated that the glucuronide
could be deconjugated in intestine to release TNP, the later
was subsequently reabsorbed into the blood to form EHC, or
metabolized by the intestinal CYP enzymes to generate
oxidative metabolites.4. Discussion
Opioid abuse and dependence impose a continuing problem
worldwide. Besides psychosocial interventions, pharma-
cotherapies are also available and proved to be effective for
opioid dependence. The drugs, that have been extensively
researched and widely used, are either full-opioid agonist
(methadone), or antagonist (naltrexone). Their efﬁciency has
evidenced by research data and clinical practices. However,
Figure 5 Mean perfusate concentration–time curves of TNP (A) and TNP-Glu (B) in in situ perfused rat intestinal preparation after
intraduodenally dosed with the spiked bile (solid symbol) or the composite bile (open symbol) (mean7SD, n¼3).
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stitutes one addiction for another, and the antagonist is unable
to retain patients in treatment due to a lack of desired positive
subjective effects14. Recently, opioid partial agonist has been
proved to be effective in reducing illicit opioid use with a good
safety proﬁle, particularly with respect to lower respiratory
depression and dependent liability compared with full
m-agonists5. The representative drug in this class is buprenor-
phine. It has been approved in the United States and other
countries for the treatment of opiate addiction, alone or in
combination with naloxone. Despite of the above advantages,
the use of buprenorphine has been restricted by its very low
oral bioavailability and potential to cause dependence both in
physical and psychological studies2. Therefore, discovery and
development of new partial opioid agonists with higher oral
bioavailability, longer duration of action and minimum abuse
liability are urgently needed.
TNP, a new chemical entities, has been selected as a drug
candidate from several dozens of buprenorphine analogs
designed and assessed in our institute. Pharmacological eva-
luation has demonstrated that TNP is a potent and long-
acting partial opioid agonist. It also showed a much longer
antagonism than buprenorphine against morphine-induced
lethality2. The results of the present study indicated that
TNP was mostly excreted from the bile as its glucuronide
conjugate with a signiﬁcant amount of 23% in 24 h. TNP-Glu
was the major circulation metabolite in the intact and the bile-
donor rats following oral administration of TNP. It also
appeared as the predominant component in the plasma of the
bile-recipient rats, indicating that the majority of the glucur-
onide conjugate excreted from bile could be reabsorbed
rapidly from rat intestine to form a substantial hepatobili-
ary-intestinal recycling. The extent of such recycling was
estimated quantitatively by comparing the AUC of bile-
recipient rats to the AUC sum of both donor and recipient
rats. The value of %EC for TNP-Glu was 42.6%, suggesting
that the bile-recipient rats could exposure to nearly half of
TNP-Glu as it is in the bile-donor rats.
TNP is an oripavine derivative. Similar to morphine and
buprenorphine, it produces 3-glucuronide conjugate, which
excretes mainly from bile and forms EHC. For morphine,
approximately half the dose (5 mg/kg) was excreted via the
bile into the intestinal tract after sc administration, largely as
morphine glucuronide15. Its EHC was driven exclusively via
the 3-glucuronide16. However, morphine glucuronide waspoorly absorbed and slowly hydrolyzed in the rat intestine.
In the case of buprenorphine, 74.1% of dose was excreted into
the bile as buprenorphine-3-glucuronide and 18.5% as norbu-
prenorphine glucuronide in 24 h after a dose (0.6 mg/kg) to
the bile-ﬁstula rat. In a paired rat study, the EHC of
buprenorphine and norbuprenorphine was conﬁrmed. Within
24 h after a buprenorphine dose to the donor rat, 58.8% of the
dose was re-excreted as norbuprenorphine-Glu in bile of the
recipient and 25.1% as buprenorphine-Glu17. Compared to
morphine and buprenorphine, the biliary excretion of TNP-
Glu was relatively lower (about 23% of dose in 24 h). The
EHC of TNP was also driven by TNP-Glu, but the secondary
peak on PK curves was only observed for TNP, not for TNP-
Glu, which indicated that the bile excreted TNP-Glu might be
absorbed rapidly from the intestine and hydrolysis of the
conjugate occurred.
It has been proved that, in the study using the in situ
perfused rat intestinal preparation, part of TNP-Glu excreted
from bile could be deconjugated by the intestinal microﬂora to
release free TNP, which was absorbed again into the circula-
tion (Fig. 5). However, in the paired rat study, a much lower
plasma concentration of TNP was observed for bile-recipient
rats when compared to the in vitro study. The %EC for TNP
was 15.6%. The previous studies have reported that TNP
could be metabolized extensively and rapidly in rats and in rat
liver microsomes in vitro7,8. Besides TNP-Glu, six oxidative
metabolites were found in the incubation with rat liver
microsomes. In the present study, oxidative metabolites, such
as dealkylated TNP, mono and di-oxidative metabolites were
also found both in the rat intestinal perfusates and in the
plasma of the bile-recipient rats. The results suggested that the
free TNP released from TNP-Glu may be metabolized by both
intestinal and hepatic enzymes before entering into blood
circulation; some of it may conjugate again to its glucuronide
metabolite, leading to a relatively lower plasma concentration
observed for the bile-recipient rats.
In pharmacological studies, TNP exhibited a more potent
and much longer antimorphine effect over buprenorphine2.
The prolonged effect of TNP is likely associated with its
pharmacokinetic properties. Despite of the fact that the
bioavailability of TNP was less than 10% and the plasma
concentrations were much lower than its conjugated metabo-
lite, the elimination of TNP from plasma was slow and the
excretion of radioactivity from the body could last for about
two weeks6. In the present study, the elimination T1/2 of TNP
Jingting Deng et al.180was signiﬁcantly shortened (Po0.05) in bile-donor rats when
compared with the intact rats. This indicates that the process
of EHC may inﬂuence the terminal concentration of TNP and
prolong the retention of the parent drug in body. In addition,
TNP-Glu has been reported to be an active metabolite of
TNP6. The higher systematic exposure and signiﬁcant EHC
of TNP-Glu may also contribute to the long acting effect of
TNP. Treatment of opioid dependence is usually a long term
effort. Longer duration of action is a desired property for
drugs used for this purpose. Prolonged retention of TNP in
body will add beneﬁt for its clinical use by reducing dose
frequency and increasing the compliance of patients.5. Conclusions
The results presented here indicate that glucuronidation is a
major metabolic pathway of TNP. Nearly one fourth of the oral
TNP dose is excreted as its glucuronide from bile within 24 h.
The enterohepatic circulation has a signiﬁcant inﬂuence on the
systemic exposure of the parent drug and its glucuronide
conjugate, particularly on the terminal elimination of TNP.
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